Medical device company Artivion (NYSE: AORT) beat Wall Street’s revenue expectations in Q3 2026, with sales up 9.2% year on year to $123.8 million. On the other hand, the company’s full-year revenue guidance of $488 million at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.08 per share was 21.2% above analysts’ consensus estimates.

Is now the time to buy AORT? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Artivion delivered revenue growth ahead of Wall Street’s expectations in the third quarter, driven by strong performance in its stent graft and On-X heart valve product lines. Management highlighted double-digit growth in both categories, with CEO Pat Mackin citing “continued execution of our strategy designed to deliver long-term profitable growth through an expanding and clinically differentiated product portfolio.” The company also benefited from increased implant activity following recent regulatory approvals, although administrative hurdles around AMDS set sales remained a near-term challenge. COO and CFO Lance Berry discussed the impact of investments in manufacturing facilities, noting supply improvements for On-X products and efforts to address margin pressures from production ramp-up.

Looking forward, Artivion’s guidance is shaped by the anticipated U.S. launch of NEXUS and ongoing efforts to overcome administrative adoption barriers for AMDS. Management emphasized that the company’s focus will remain on expanding manufacturing capacity, building inventory, and supporting value analysis committees ahead of NEXUS’s commercial debut. Mackin stated, “Interest across the clinical community has continued to build, and we look forward to conducting our first surgeon training event in December.” The company also pointed to its innovation pipeline, including the ARTIZEN trial, as a key component for long-term market expansion, while acknowledging that transitioning away from PerClot will present some top-line headwinds in the coming years.

Key insights from management’s remarks

Management attributed the quarter’s revenue growth to robust stent graft and On-X valve adoption, progress on U.S. regulatory approvals, and strategic manufacturing investments, but noted persistent administrative hurdles and evolving product mix as margin headwinds.

• Stent graft adoption drives growth: Artivion reported 12% constant currency growth in stent graft revenues, supported by increased AMDS implant activity post-FDA approval and strong international demand, though set sales faced continued administrative challenges.
• On-X supply improvements: Management highlighted mid-teens U.S. growth for On-X heart valves, attributing improved supply and manufacturing investments at the Austin facility as pivotal for meeting global demand and supporting future international expansion.
• NEXUS launch preparations: Efforts to build inventory, expand manufacturing, and conduct surgeon training are underway for the U.S. commercial launch of NEXUS, with management noting positive early clinical feedback and unique adoption dynamics compared to AMDS.
• Product mix and margin impact: The quarter’s gross margin decline was attributed to unfavorable product mix, investments in manufacturing ramp-up for On-X and NEXUS, and nonrecurring period charges, with Berry expecting normalization as production volumes increase.
• PerClot transition winds down: Revenue in the “other” segment surged due to PerClot, but the upcoming end of the Baxter supply agreement is expected to create future headwinds, shifting management’s attention to core business and pipeline execution.

Drivers of future performance

Artivion’s outlook centers on the NEXUS U.S. launch, continued AMDS adoption, and operational efficiency, while anticipating margin recovery and headwinds from the PerClot transition.

• NEXUS launch as growth catalyst: Management expects the NEXUS platform to begin contributing U.S. revenue in early 2027, with a streamlined adoption process due to elective case status and reduced upfront purchasing requirements compared to AMDS. Initial surgeon feedback has been favorable, and the sales team is being expanded in preparation for the launch.
• AMDS adoption and administrative hurdles: While implant volumes for AMDS are rising, management acknowledged ongoing administrative challenges in securing hospital purchasing approvals for starter sets. Mackin emphasized continued initiatives to lower these barriers, predicting that set sale difficulties will prove temporary as more accounts are onboarded.
• Margin and product mix dynamics: Berry indicated that gross margins should improve as manufacturing investments in On-X and NEXUS drive higher production efficiency, but also flagged that the expiration of the PerClot supply agreement will reduce revenue growth and EBITDA by 2 and 4 percentage points, respectively, in the subsequent year.

Catalysts in upcoming quarters

Over the coming quarters, the StockStory team will monitor (1) the pace of NEXUS U.S. launch execution and surgeon adoption, (2) whether AMDS set sale barriers can be lowered to accelerate implant volume growth, and (3) the impact of manufacturing investments on gross margin recovery. We will also watch for updates from the ARTIZEN trial and any shifts in the competitive landscape for aortic repair technologies.

Artivion currently trades at $25.23, in line with $25.29 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.